Envestnet Asset Management Inc. Sells 3,145 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Envestnet Asset Management Inc. trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 2.6% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 117,527 shares of the medical equipment provider's stock after selling 3,145 shares during the quarter. Envestnet Asset Management Inc. owned about 0.17% of Lantheus worth $10,514,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. State of New Jersey Common Pension Fund D grew its holdings in shares of Lantheus by 0.4% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock worth $2,364,000 after acquiring an additional 115 shares during the period. Bleakley Financial Group LLC grew its stake in shares of Lantheus by 6.1% during the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock valued at $200,000 after purchasing an additional 129 shares during the period. Avantax Advisory Services Inc. increased its position in shares of Lantheus by 5.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock valued at $213,000 after purchasing an additional 132 shares during the last quarter. Foundry Partners LLC boosted its holdings in shares of Lantheus by 4.5% in the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock worth $278,000 after buying an additional 133 shares during the last quarter. Finally, UMB Bank n.a. grew its position in Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares during the period. Hedge funds and other institutional investors own 99.06% of the company's stock.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 63,109 shares of company stock valued at $6,016,046. Corporate insiders own 2.00% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. B. Riley dropped their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Truist Financial boosted their price target on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Finally, JMP Securities restated a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Stock Performance

Shares of Lantheus stock traded up $0.58 during trading hours on Thursday, hitting $101.78. The company's stock had a trading volume of 73,836 shares, compared to its average volume of 950,340. Lantheus Holdings, Inc. has a 12-month low of $63.61 and a 12-month high of $126.89. The business has a 50 day moving average price of $96.54 and a two-hundred day moving average price of $95.40. The company has a market cap of $6.97 billion, a PE ratio of 16.92 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.